Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupAggressive LymphomasDermatologic OncologyIndolent LymphomasDiseaseNHL, B-Cell Type, CutaneousSubgroupCD20+ICD10C82.-C83.-MeSHSequenceAntineoplastic therapySubstanceRituximabSubstanceRituximabSubstanceRituximabSubstanceRituximabNo. Substances1 RadiotherapySupportive therapySubstanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneSubstanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneSubstanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneSubstanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneNo. Substances4Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorBrandenburg ADiseaseprimäres, kutanes B-Zell-LymphomOriginDepartment of Dermatology and Allergy, Skin cancer centre Charité, Charité-Universitätsmedizin BerlinProtocols in Revision 1 protocol foundRituximab 375, cutaneous B-cell lymphoma (PID1390 V1.0)
